<div class="headers"><div>Figure 1—HbA1c efﬁcacy analysis: Data are from patients treated with $1 dose of study drug who had a baseline and $1 on-treatment HbA1c measurement. C: Placebo-corrected change from baseline in HbA1c with empagliﬂozin at week 26 in subgroups by baseline HbA1c (,8% and $8%). Data are based on mixed-model repeated measures analysis. **P , 0.001 for difference vs. placebo; ***P , 0.0001 for difference vs. placebo</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Figure 1—HbA1c efﬁcacy analysis: Data are from patients treated with $1 dose of study drug who had a baseline and $1 on-treatment HbA1c measurement. C: Placebo-corrected change from baseline in HbA1c with empagliﬂozin at week 26 in subgroups by baseline HbA1c (,8% and $8%). Data are based on mixed-model repeated measures analysis. **P , 0.001 for difference vs. placebo; ***P , 0.0001 for difference vs. placebo</p></td>
</tr>
</tbody>
</table>
